Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

STRATA Skin Sciences (SSKN) EBITDA Margin (2016 - 2025)

STRATA Skin Sciences' EBITDA Margin history spans 14 years, with the latest figure at 41.71% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 8646.0% to 41.71% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.27%, a 2330.0% increase, with the full-year FY2025 number at 4.27%, up 2330.0% from a year prior.
  • EBITDA Margin hit 41.71% in Q4 2025 for STRATA Skin Sciences, up from 16.93% in the prior quarter.
  • Over the last five years, EBITDA Margin for SSKN hit a ceiling of 41.71% in Q4 2025 and a floor of 44.75% in Q4 2024.
  • Historically, EBITDA Margin has averaged 18.56% across 5 years, with a median of 18.43% in 2022.
  • Biggest five-year swings in EBITDA Margin: tumbled -4087bps in 2023 and later skyrocketed 8646bps in 2025.
  • Tracing SSKN's EBITDA Margin over 5 years: stood at 6.87% in 2021, then surged by 118bps to 1.26% in 2022, then plummeted by -3233bps to 39.6% in 2023, then fell by -13bps to 44.75% in 2024, then surged by 193bps to 41.71% in 2025.
  • Business Quant data shows EBITDA Margin for SSKN at 41.71% in Q4 2025, 16.93% in Q3 2025, and 30.14% in Q2 2025.